Is Retatrutide Legal? Global Status Guide
Category: Weight Loss · Tracked in 158 countries
29
Legal1
Research Only124
Grey Area1
Prescription3
BannedCan You Buy Retatrutide?
Whether you can buy Retatrutide depends on your country. It is legal to purchase in 29 countries, including Jamaica, Dominican Republic, Bahamas, Trinidad and Tobago, Barbados, Cayman Islands, Aruba, Curacao, and 21 more. A prescription is required in 1 countries, including Australia. It falls into a legal grey area in 124 countries (United States, Canada, Germany, France, Netherlands, Sweden, Norway, Denmark, and 116 more), where it may be available for research but not for human use. It is banned in 3 countries: Cuba, China, Singapore.
Traveling with Retatrutide
Traveling internationally with Retatrutide requires understanding local laws at your destination. Do not carry Retatrutide into countries where it is banned (Cuba, China, Singapore) — you could face serious legal consequences. In countries requiring a prescription (Australia), carry a valid prescription or doctor's letter. Always declare pharmaceutical products at customs and check the latest regulations before traveling.
Need to calculate your Retatrutide dosage? Use the Retatrutide reconstitution calculator on peptide.locker
Retatrutide Legal Status by Country (158)
| Country | Status | Rx Required | Schedule | Detail |
|---|---|---|---|---|
| Anguilla | Legal | No | Not Scheduled | Not approved anywhere. Not specifically addressed. |
| Antigua and Barbuda | Legal | No | Not Scheduled | Not approved anywhere. Not addressed. |
| Aruba | Legal | No | Unregistered | Not approved anywhere globally. Not specifically addressed. |
| Bahamas | Legal | No | Unregistered | Not approved anywhere globally. Not specifically addressed. |
| Barbados | Legal | No | Unregistered | Not approved anywhere globally. Not specifically addressed. |
| Bosnia and Herzegovina | Legal | No | Not Registered | Non-EU. Not registered. Phase 3 trials. Falls outside ALMBIH oversight. |
| British Virgin Islands | Legal | No | Not Scheduled | Not approved anywhere. Not specifically addressed. |
| Cayman Islands | Legal | No | Unregistered | Not approved anywhere globally. Not specifically addressed. |
| Costa Rica | Legal | No | Unregistered | Not approved anywhere globally. Not specifically addressed. |
| Curacao | Legal | No | Unregistered | Not approved anywhere globally. Not specifically addressed. |
| Dominica | Legal | No | Not Scheduled | Not approved anywhere. Not addressed. |
| Dominican Republic | Legal | No | Unregistered | Not approved anywhere globally. Not specifically addressed. |
| Georgia | Legal | No | Not Registered | Non-EU. Not registered. Phase 3 trials. Falls outside current regulatory scope. Liberal pharmaceutical access environment means availability through various channels. |
| Grenada | Legal | No | Not Scheduled | Not approved anywhere. Not addressed. |
| Jamaica | Legal | No | Unregistered | Not approved anywhere globally. Not specifically addressed. |
| Montenegro | Legal | No | Not Registered | Non-EU. Not registered. Phase 3 trials. Falls outside CALIMS oversight. |
| Montserrat | Legal | No | Not Scheduled | Not approved anywhere. Not specifically addressed. |
| North Macedonia | Legal | No | Not Registered | Non-EU. Not registered. Phase 3 trials. Falls outside MALMED oversight. |
| Papua New Guinea | Legal | No | Not Scheduled | Investigational drug. Not registered in PNG. No local market or enforcement. |
| Samoa | Legal | No | Not Scheduled | Investigational drug. Not available or regulated in Samoa. |
| Serbia | Legal | No | Not Registered | Non-EU. Not registered. Phase 3 clinical trials. Falls outside ALIMS oversight as not a registered medicine. Available from online research vendors. |
| St Kitts and Nevis | Legal | No | Not Scheduled | Not approved anywhere. Not addressed. |
| St Lucia | Legal | No | Not Scheduled | Not approved anywhere. Not addressed. |
| St Vincent and the Grenadines | Legal | No | Not Scheduled | Not approved anywhere. Not addressed. |
| Tonga | Legal | No | Not Scheduled | Investigational drug. Not available or regulated in Tonga. |
| Trinidad and Tobago | Legal | No | Unregistered | Not approved anywhere globally. Not specifically addressed. |
| Turks and Caicos | Legal | No | Not Scheduled | Not approved anywhere. Not specifically addressed. |
| Ukraine | Legal | No | Not Registered | Non-EU. Not registered. Phase 3 clinical trials. Falls outside SMDC oversight as not registered. Wartime simplified registration does not apply to investigational drugs. |
| Vanuatu | Legal | No | Not Scheduled | Investigational drug. Not available or regulated in Vanuatu. |
| United Kingdom | Research Only | No | Not Scheduled | Investigational compound. Not MHRA approved. Available as research chemical. Not specifically targeted. |
| Algeria | Grey Area | No | Unregistered | Investigational compound. Not ANPP registered. Cannot meet import requirement of prior marketing in country of origin. |
| Andorra | Grey Area | No | Not Scheduled | Investigational drug. Not authorized by AMA. |
| Angola | Grey Area | No | Unregistered | Investigational compound. Not INABEC registered. Not available in Angolan market. |
| Argentina | Grey Area | No | Investigational | Phase 3 globally. Not approved in any LATAM country. |
| Austria | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Any online sales illegal. FDA warned against compounded versions. |
| Bahrain | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Bangladesh | Grey Area | No | Not Scheduled | Investigational drug. Not registered with DGDA. |
| Belgium | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Any online sales illegal. FDA warned against compounded versions. |
| Belize | Grey Area | No | Investigational | Phase 3 globally. Not approved in any LATAM country. |
| Bolivia | Grey Area | No | Investigational | Phase 3 globally. Not approved in any LATAM country. |
| Bonaire | Grey Area | No | Not Scheduled | Not approved. Not specifically addressed. |
| Botswana | Grey Area | No | Unregistered | Investigational compound. Not BoMRA registered. Would require marketing authorization. |
| Brazil | Grey Area | No | Investigational | Phase 3 globally. Not approved in any LATAM country. |
| Brunei | Grey Area | No | Not Scheduled | Investigational drug. Not registered. Cannot be legally imported. |
| Bulgaria | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Not authorized for sale. |
| Cambodia | Grey Area | No | Investigational | Not specifically regulated. Would be available through same channels as other peptides if imported. |
| Cameroon | Grey Area | No | Unregistered | Investigational compound. Not registered. Import would require AOI which is not available for unregistered products. |
| Canada | Grey Area | No | Not Scheduled (CDSA) | No Health Canada DIN. Investigational compound. Would be treated same as other unauthorized GLP-1 peptides. Compounding not permitted. |
| Cape Verde | Grey Area | No | Unregistered | Investigational compound. Not ARFA registered. Not available in Cape Verdean market. |
| Chile | Grey Area | No | Investigational | Phase 3 globally. Not approved in any LATAM country. |
| Colombia | Grey Area | No | Investigational | Phase 3 globally. Not approved in any LATAM country. |
| Croatia | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Not authorized for sale. |
| Cyprus | Grey Area | No | Not Scheduled | Investigational drug. No EMA or national marketing authorization. Clinical trial use only. |
| Czech Republic | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Any online sales illegal. FDA warned against compounded versions. |
| Democratic Republic of Congo | Grey Area | No | Unregistered | Investigational compound. Not registered. Not available in DRC market. |
| Denmark | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Any online sales illegal. FDA warned against compounded versions. |
| Ecuador | Grey Area | No | Investigational | Phase 3 globally. Not approved in any LATAM country. |
| Egypt | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| El Salvador | Grey Area | No | Investigational | Phase 3 globally. Not approved in any LATAM country. |
| Estonia | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Not authorized for sale. |
| Ethiopia | Grey Area | No | Unregistered | Investigational compound. Not EFDA registered. No specific GLP-1 class regulation beyond registered products. Not available in Ethiopian market. |
| Fiji | Grey Area | No | Investigational | Not approved in any jurisdiction. Not available locally. Would require import permit if classified as medicine. |
| Finland | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Any online sales illegal. FDA warned against compounded versions. |
| France | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Any online sales illegal. FDA warned against compounded versions. |
| French Guiana | Grey Area | No | Investigational | Not approved. French pharma law applies. |
| Germany | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Any online sales illegal. FDA warned against compounded versions. |
| Ghana | Grey Area | No | Investigational | Investigational. Not approved. |
| Greece | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Any online sales illegal. FDA warned against compounded versions. |
| Guatemala | Grey Area | No | Investigational | Phase 3 globally. Not approved in any LATAM country. |
| Guyana | Grey Area | No | Investigational | Phase 3 globally. Not approved in any LATAM country. |
| Honduras | Grey Area | No | Investigational | Phase 3 globally. Not approved in any LATAM country. |
| Hong Kong | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Hungary | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Not authorized for sale. Moderate enforcement. |
| Iceland | Grey Area | No | Investigational | Not EMA authorized. No marketing authorization. Cannot be legally marketed or imported for human use. |
| India | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Indonesia | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Iran | Grey Area | No | Not Scheduled | Investigational drug. Not registered with IFDA. Not available due to sanctions and lack of approval. |
| Iraq | Grey Area | No | Not Scheduled | Investigational drug. Not registered. Could potentially enter through unregulated import channels. |
| Ireland | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Any online sales illegal. FDA warned against compounded versions. |
| Israel | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Italy | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Any online sales illegal. FDA warned against compounded versions. |
| Ivory Coast | Grey Area | No | Unregistered | Investigational compound. Not registered. Not available in Ivorian market. |
| Japan | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Jordan | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Kenya | Grey Area | No | Investigational | Investigational. Not PPB registered. Given PPB warnings on Ozempic misuse, GLP-1 class under scrutiny. |
| Kuwait | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Laos | Grey Area | No | Investigational | Not approved. Not available locally. |
| Latvia | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Not authorized for sale. |
| Lebanon | Grey Area | No | Not Scheduled | Investigational drug. Not registered. Not available. |
| Libya | Grey Area | No | Unregistered | Investigational compound. Not registered. Not available in Libyan market. Import subject to ACI requirements. |
| Liechtenstein | Grey Area | No | Not Scheduled | Investigational drug. No EMA authorization. Not available. |
| Lithuania | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Not authorized for sale. |
| Luxembourg | Grey Area | No | Not Scheduled | Investigational drug. No EMA or national authorization. |
| Madagascar | Grey Area | No | Unregistered | Investigational compound. Not AMM registered. Not available in Malagasy market. |
| Malawi | Grey Area | No | Unregistered | Investigational compound. Not PMRA registered. Not available in Malawian market. |
| Malaysia | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Maldives | Grey Area | No | Investigational | Not approved. Not available locally. |
| Malta | Grey Area | No | Investigational | Not EMA authorized. Cannot be marketed or imported for human use without authorization. |
| Mauritius | Grey Area | No | Investigational | Investigational. Not approved. |
| Mexico | Grey Area | No | Unregistered | Not COFEPRIS approved. Phase 3 globally. Not yet available at clinics. |
| Monaco | Grey Area | No | Not Scheduled | Investigational drug. No authorization. Same as France. |
| Morocco | Grey Area | No | Investigational | Not approved. Investigational. No AMM. Given AMMPS approval of Ozempic, GLP-1 class is on regulatory radar. |
| Mozambique | Grey Area | No | Unregistered | Investigational compound. Not ANARME registered. Not available in Mozambican market. |
| Myanmar | Grey Area | No | Investigational | Not specifically regulated. Would be importable through informal channels. |
| Namibia | Grey Area | No | Investigational | Investigational. Not approved. |
| Nepal | Grey Area | No | Investigational | Not approved. Not available locally. |
| Netherlands | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Any online sales illegal. FDA warned against compounded versions. |
| New Zealand | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Nicaragua | Grey Area | No | Investigational | Phase 3 globally. Not approved in any LATAM country. |
| Nigeria | Grey Area | No | Investigational | Investigational. Not approved. Given NAFDAC alerts on falsified Ozempic, GLP-1 class under scrutiny. |
| Norway | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Any online sales illegal. FDA warned against compounded versions. |
| Oman | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Pakistan | Grey Area | No | Not Scheduled | Investigational drug. Not registered with DRAP. |
| Panama | Grey Area | No | Investigational | Phase 3 globally. Not approved in any LATAM country. |
| Paraguay | Grey Area | No | Investigational | Phase 3 globally. Not approved in any LATAM country. |
| Peru | Grey Area | No | Investigational | Phase 3 globally. Not approved in any LATAM country. |
| Philippines | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Poland | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Any online sales illegal. FDA warned against compounded versions. |
| Portugal | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Any online sales illegal. FDA warned against compounded versions. |
| Qatar | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Romania | Grey Area | No | Investigational | Phase 3 clinical trials (Eli Lilly). No EMA approval. Not authorized for sale. Research chemical gray market exists. |
| Russia | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Rwanda | Grey Area | No | Investigational | Investigational. Not approved. |
| Saba | Grey Area | No | Not Scheduled | Not approved. Not specifically addressed. |
| Saint Barthelemy | Grey Area | No | Investigational | Not approved. French pharma law applies. |
| Saint Martin (French) | Grey Area | No | Investigational | Not approved. French pharma law applies. |
| Saudi Arabia | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Senegal | Grey Area | No | Investigational | Investigational. Not approved. |
| Seychelles | Grey Area | No | Investigational | Not approved. Not available locally. |
| Sint Eustatius | Grey Area | No | Not Scheduled | Not approved. Not specifically addressed. |
| Sint Maarten | Grey Area | No | Not Scheduled | Not approved. Not specifically addressed. |
| Slovakia | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Not authorized for sale. |
| Slovenia | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Not authorized for sale. |
| South Africa | Grey Area | No | Unregistered | Investigational GLP-1/GIP/glucagon triple agonist. Not SAHPRA registered. Phase 3 trials globally. Would fall under SAHPRA enforcement against unregistered GLP-1 products if marketed for human use. Available from research vendors. |
| South Korea | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Spain | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Any online sales illegal. FDA warned against compounded versions. |
| Sri Lanka | Grey Area | No | Investigational | Not approved in any reference jurisdiction. Cannot be registered. |
| Suriname | Grey Area | No | Investigational | Phase 3 globally. Not approved in any LATAM country. |
| Sweden | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Any online sales illegal. FDA warned against compounded versions. |
| Switzerland | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Any online sales illegal. FDA warned against compounded versions. |
| Taiwan | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Tanzania | Grey Area | No | Investigational | Investigational. Not TMDA approved. |
| Thailand | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Tunisia | Grey Area | No | Investigational | Investigational. Not approved in Tunisia. Phase 3 globally. |
| Turkey | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Uganda | Grey Area | No | Unregistered | Investigational compound. Not NDA registered. Not available in Ugandan market. |
| United Arab Emirates | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| United States | Grey Area | No | Not Scheduled | Investigational new drug. Not FDA-approved. Not yet on Category 2 list. Available from research chemical vendors. FDA has not specifically targeted retatrutide enforcement yet. |
| Uruguay | Grey Area | No | Investigational | Phase 3 globally. Not approved in any LATAM country. |
| US Virgin Islands | Grey Area | No | Not Scheduled | Same as US. Investigational. Not FDA approved. |
| Venezuela | Grey Area | No | Investigational | Phase 3 globally. Not approved in any LATAM country. |
| Vietnam | Grey Area | No | Investigational | Phase 3 globally. Not approved. |
| Zambia | Grey Area | No | Unregistered | Investigational compound. Not ZAMRA registered. Import requires authorization. |
| Zimbabwe | Grey Area | No | Unregistered | Investigational compound. Not MCAZ registered. Import requires authorization. |
| Australia | Prescription | Yes | Schedule 4 | GLP-1 receptor agonists captured under Schedule 4. Compounding of GLP-1 RAs banned from 1 October 2024. |
| China | Banned | No | Unapproved Drug | Not approved. Clinical trials may exist. |
| Cuba | Banned | No | State Controlled | State pharmaceutical monopoly via CECMED/BioCubaFarma. No private purchase/import permitted. |
| Singapore | Banned | No | Unapproved Health Product | Not approved. Do not import. |
Data is researcher-verified but not legal advice. Regulations change frequently. Always verify with local authorities before purchasing, importing, or traveling with peptides. Last verified: 2026-02-28.